Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose—the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial”

Detalles Bibliográficos
Autores principales: Karlsson, Jan Olof G., Jynge, Per, Lundström, Ingemar, Ignarro, Louis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591909/
https://www.ncbi.nlm.nih.gov/pubmed/31234946
http://dx.doi.org/10.1186/s13063-019-3476-3
_version_ 1783429803953618944
author Karlsson, Jan Olof G.
Jynge, Per
Lundström, Ingemar
Ignarro, Louis J.
author_facet Karlsson, Jan Olof G.
Jynge, Per
Lundström, Ingemar
Ignarro, Louis J.
author_sort Karlsson, Jan Olof G.
collection PubMed
description
format Online
Article
Text
id pubmed-6591909
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65919092019-07-08 Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose—the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial” Karlsson, Jan Olof G. Jynge, Per Lundström, Ingemar Ignarro, Louis J. Trials Letter BioMed Central 2019-06-24 /pmc/articles/PMC6591909/ /pubmed/31234946 http://dx.doi.org/10.1186/s13063-019-3476-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter
Karlsson, Jan Olof G.
Jynge, Per
Lundström, Ingemar
Ignarro, Louis J.
Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose—the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial”
title Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose—the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial”
title_full Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose—the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial”
title_fullStr Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose—the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial”
title_full_unstemmed Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose—the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial”
title_short Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose—the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial”
title_sort letter in response to: “randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of n acetylcysteine for paracetamol overdose—the pp100-01 for overdose of paracetamol (pop) trial: study protocol for a randomised controlled trial”
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591909/
https://www.ncbi.nlm.nih.gov/pubmed/31234946
http://dx.doi.org/10.1186/s13063-019-3476-3
work_keys_str_mv AT karlssonjanolofg letterinresponsetorandomisedopenlabelexploratorysafetyandtolerabilitystudywithcalmangafodipirinpatientstreatedwiththe12hregimenofnacetylcysteineforparacetamoloverdosethepp10001foroverdoseofparacetamolpoptrialstudyprotocolforarandomisedcontrolledtrial
AT jyngeper letterinresponsetorandomisedopenlabelexploratorysafetyandtolerabilitystudywithcalmangafodipirinpatientstreatedwiththe12hregimenofnacetylcysteineforparacetamoloverdosethepp10001foroverdoseofparacetamolpoptrialstudyprotocolforarandomisedcontrolledtrial
AT lundstromingemar letterinresponsetorandomisedopenlabelexploratorysafetyandtolerabilitystudywithcalmangafodipirinpatientstreatedwiththe12hregimenofnacetylcysteineforparacetamoloverdosethepp10001foroverdoseofparacetamolpoptrialstudyprotocolforarandomisedcontrolledtrial
AT ignarrolouisj letterinresponsetorandomisedopenlabelexploratorysafetyandtolerabilitystudywithcalmangafodipirinpatientstreatedwiththe12hregimenofnacetylcysteineforparacetamoloverdosethepp10001foroverdoseofparacetamolpoptrialstudyprotocolforarandomisedcontrolledtrial

Ejemplares similares